- Home
- DXLG vs IFRX Comparison
DXLG vs IFRX Comparison
Compare DXLG & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- IFRX
- Stock Information
- Founded
- DXLG 1976
- IFRX 2007
- Country
- DXLG United States
- IFRX Germany
- Employees
- DXLG N/A
- IFRX N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- DXLG Consumer Discretionary
- IFRX Health Care
- Exchange
- DXLG Nasdaq
- IFRX Nasdaq
- Market Cap
- DXLG 156.7M
- IFRX 143.7M
- IPO Year
- DXLG 1987
- IFRX 2017
- Fundamental
- Price
- DXLG $2.41
- IFRX $2.17
- Analyst Decision
- DXLG Buy
- IFRX Strong Buy
- Analyst Count
- DXLG 2
- IFRX 1
- Target Price
- DXLG $3.50
- IFRX $8.00
- AVG Volume (30 Days)
- DXLG 264.3K
- IFRX 420.2K
- Earning Date
- DXLG 11-22-2024
- IFRX 11-08-2024
- Dividend Yield
- DXLG N/A
- IFRX N/A
- EPS Growth
- DXLG N/A
- IFRX N/A
- EPS
- DXLG 0.15
- IFRX N/A
- Revenue
- DXLG $484,954,000.00
- IFRX $187,930.00
- Revenue This Year
- DXLG N/A
- IFRX $435.15
- Revenue Next Year
- DXLG $2.85
- IFRX $180.44
- P/E Ratio
- DXLG $16.41
- IFRX N/A
- Revenue Growth
- DXLG N/A
- IFRX 177.12
- 52 Week Low
- DXLG $2.19
- IFRX $1.17
- 52 Week High
- DXLG $4.76
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- DXLG 38.53
- IFRX 50.82
- Support Level
- DXLG $2.40
- IFRX $2.13
- Resistance Level
- DXLG $2.69
- IFRX $2.74
- Average True Range (ATR)
- DXLG 0.13
- IFRX 0.24
- MACD
- DXLG -0.00
- IFRX -0.05
- Stochastic Oscillator
- DXLG 8.57
- IFRX 24.54
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.